Sign up to save your podcasts
Or
Share How AI is Reprogramming Human Biology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How AI is Reprogramming Human Biology
Welcome to today's deep dive episode, where we explore the thrilling intersection of Artificial Intelligence and human longevity.
For decades, discovering a new drug has been an agonizingly slow and expensive process, typically costing billions of dollars and taking ten to twenty years to reach the market. But today, we are standing at the edge of a medical revolution. AI-enabled workflows are already compressing early drug discovery timelines by 30 to 40 percent. Breakthroughs like Google DeepMind's AlphaFold have successfully predicted the structures of over 200 million proteins, solving a 50-year-old grand challenge in biology and ushering in a new era of "digital biology" and rational drug design.But what if AI couldn't just cure disease, but actually slow down the aging process itself?In this episode, we will unpack how machine learning is hunting down "senolytics"—revolutionary anti-aging drugs that kill off senescent "zombie cells" which accumulate in our bodies over a lifetime and drive age-related diseases. We'll look at a stunning recent experiment where an AI model screened over 4,300 molecules in just five minutes, discovering highly effective anti-aging compounds like oleandrin that would have normally taken weeks of intensive labor and tens of thousands of dollars to test in a lab. We will also explore how AI, combined with advanced microscopy, is decoding complex age-related proteins like PAPP-A to inform novel longevity therapies.Finally, we will tackle the societal implications of these breakthroughs. Right now, there is a massive socio-economic "longevity gap," where the wealthiest individuals live significantly longer, healthier lives than those in poorer areas. We'll discuss how AI algorithms, fueled by data from wearables, genetics, and biomarkers, can democratize access to personalized health insights—ensuring that life-extending innovations benefit the many, rather than just the privileged few.Grab your headphones and settle in, because the quest to rewrite the limits of the human lifespan has officially begun.
View all episodes
By YeekWelcome to today's deep dive episode, where we explore the thrilling intersection of Artificial Intelligence and human longevity.
For decades, discovering a new drug has been an agonizingly slow and expensive process, typically costing billions of dollars and taking ten to twenty years to reach the market. But today, we are standing at the edge of a medical revolution. AI-enabled workflows are already compressing early drug discovery timelines by 30 to 40 percent. Breakthroughs like Google DeepMind's AlphaFold have successfully predicted the structures of over 200 million proteins, solving a 50-year-old grand challenge in biology and ushering in a new era of "digital biology" and rational drug design.But what if AI couldn't just cure disease, but actually slow down the aging process itself?In this episode, we will unpack how machine learning is hunting down "senolytics"—revolutionary anti-aging drugs that kill off senescent "zombie cells" which accumulate in our bodies over a lifetime and drive age-related diseases. We'll look at a stunning recent experiment where an AI model screened over 4,300 molecules in just five minutes, discovering highly effective anti-aging compounds like oleandrin that would have normally taken weeks of intensive labor and tens of thousands of dollars to test in a lab. We will also explore how AI, combined with advanced microscopy, is decoding complex age-related proteins like PAPP-A to inform novel longevity therapies.Finally, we will tackle the societal implications of these breakthroughs. Right now, there is a massive socio-economic "longevity gap," where the wealthiest individuals live significantly longer, healthier lives than those in poorer areas. We'll discuss how AI algorithms, fueled by data from wearables, genetics, and biomarkers, can democratize access to personalized health insights—ensuring that life-extending innovations benefit the many, rather than just the privileged few.Grab your headphones and settle in, because the quest to rewrite the limits of the human lifespan has officially begun.